Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 21, 2011; 17(3): 334-342
Published online Jan 21, 2011. doi: 10.3748/wjg.v17.i3.334
Published online Jan 21, 2011. doi: 10.3748/wjg.v17.i3.334
All patients | Group A calcium/vitamin D | Group B + sodium fluoride | Group C + ibandronate | |
No. of patients | 123 | 27 | 47 | 49 |
Patients with fractures, n (%) | 29 (23.6) | 6 (22.2) | 9 (19.2) | 14 (28.6) |
No. of fractures | 56 | 10 | 18 | 28 |
New fractures (n) | 1 | 0 | 1 | 0 |
T-score lumbar spine | -1.80 ± 0.34 | -1.57 ± 0.31 | -1.82 ± 0.40 | -1.91 ± 0.04 |
BMD lumbar spine (g/cm2) | 0.87 ± 0.05 | 0.90 ± 0.04 | 0.87 ± 0.05 | -0.86 ± 0.04 |
Follow-up (yr) | 2.65 ± 1.00 | 2.58 ± 1.00 | 2.92 ± 0.89 | 2.44 ± 1.17 |
- Citation: Klaus J, Reinshagen M, Herdt K, Schröter C, Adler G, Boyen GBV, Tirpitz CV. Bones and Crohn’s: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World J Gastroenterol 2011; 17(3): 334-342
- URL: https://www.wjgnet.com/1007-9327/full/v17/i3/334.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i3.334